UGT2B28: A Drug Target / Disease Biomarker (G54490)

Target Name: UGT2B28

NCBI ID: G54490

UGT2B28

UGT2B28: A Drug Target / Disease Biomarker

UGT2B28 is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, HIV, and cardiovascular disease. Its unique genetic mutation has been linked to the development of certain inherited liver diseases, making it an attractive target for researchers looking for new treatments.

The UGT2B28 gene is a member of the UGT family, which is responsible for metabolizing a wide variety of drugs and other substances in the body. The UGT2B28 gene is specifically associated with the function of the UGT2B28 enzyme, which is responsible for metabolizing the chemotherapy drug irinotecan.

Studies have shown that individuals with the UGT2B28 mutation are at increased risk of developing certain inherited liver diseases, including biliary tract cancer and cirrhosis. This suggests that the UGT2B28 enzyme may play a role in the development and progression of these diseases.

In addition to its potential as a drug target, the UGT2B28 gene has also been identified as a potential biomarker for several diseases. For example, research has shown that individuals with the UGT2B28 mutation may be more likely to develop certain types of cancer, including colon cancer and lung cancer.

The discovery of the UGT2B28 gene as a potential drug target or biomarker has the potential to lead to new treatments for a range of diseases. For example, studies have shown that irinotecan, a chemotherapy drug that is often used to treat biliary tract cancer, is not effective in individuals with the UGT2B28 mutation. Researchers may be able to use this information to develop new treatments for this disease.

In addition to its potential as a drug target, the UGT2B28 gene has also been identified as a potential biomarker for several other diseases, including cardiovascular disease and HIV. For example, research has shown that individuals with the UGT2B28 mutation may be at increased risk of developing certain cardiovascular conditions, such as heart failure and stroke.

The discovery of the UGT2B28 gene as a potential drug target or biomarker has the potential to lead to new treatments for a range of diseases. However, further research is needed to fully understand its role and potential as a drug target or biomarker.

In conclusion, the UGT2B28 gene is a promising target for research into the development and treatment of a range of diseases. Further studies are needed to fully understand its role and potential as a drug target or biomarker.

Protein Name: UDP Glucuronosyltransferase Family 2 Member B28

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:11300766). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:11300766). Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (androsterone, 3alpha-androstanediol) and estrogens (estradiol, estrone) (PubMed:11300766). Catalyzes the glucuronidation of bile acid substrates, which are natural detergents for dietary lipids absorption (PubMed:11300766). Displays glucuronidation activity toward the phenolic compounds eugenol (PubMed:11300766)

The "UGT2B28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets